# Neoadjuvant Treatment of Breast Cancer

> **NCT00254592** · PHASE2 · COMPLETED · sponsor: **University of California, Irvine** · enrollment: 43 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Carboplatin
- **DRUG:** Nab-paclitaxel
- **DRUG:** GM-CSF
- **DRUG:** Trastuzumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00254592
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2013-09-04
- **Final completion:** 2013-09-04
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2019-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00254592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00254592, "Neoadjuvant Treatment of Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00254592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*